The article provides an overview of the social and economic effects of restructuring healthcare on the basis of regular use of genetic data. The review covers such problems as medical efficiency of the proposed model, its affordability and economic efficiency (micro and macro levels), and external (technical, behavioral, ethical, and legal) constraints. Empirical studies indicate low medical and economic efficiency of universal coverage of whole genome sequencing. For most diseases, genome analysis does not allow one to take adequate measures to prevent risk of suffering from it given the lack of information about its genetic nature, the limited role of genetic factors in onset and progression of diseases and the absence of effective low risk management practices. The combination of rarity of significant genetic variants and low efficiency of early prevention leads to worse efficiency of universal genetic screening compared with traditional preventive measures. Promising directions for genome medical technologies in the short and medium term are diagnosis of hereditary diseases and strong predisposition to certain diseases as well as drug therapy personalization. The rate of adoption of new technologies in regular clinical practice will be determined by the willingness of the state and private entities to invest in the required infrastructure, including creating national banks for genetic data, acquiring equipment for analysis and storing the data obtained, and training of qualified personnel. At the moment Russia has a backlog of several years in this area compared with advanced countries. The national program for the development of genetic technologies, capable of closing the gap, is expected to be approved in early 2019.
Планирование объемов и финансовых затрат на оказание медицинской помощи в стационарных условиях на федеральном и региональном уровнях Фармакоэкономическая эффективность вакцинопрофилактики гриппа и пневмококковой инфекции у работников ОАО «РЖД» с точки зрения работодателя PHARMACOECONOMICS. Modern Pharmacoeconomics and Pharmacoepidemiology ISSN 2070-4909 2015 Vol. 8 No4 www.pharmacoeconomics.ru Данная интернет-версия статьи была скачана с сайта http://www.pharmacoeconomics.ru. Не предназначено для использования в коммерческих целях. Информацию о репринтах можно получить в редакции. Тел.:
Pandemic, caused by the SARS-CoV-2 coronavirus, has resulted in economic slowdown all over the world, and in Russia too. This may require midand longterm adjustments in some policy areas, including health and demography. In current circumstances a number of measures could be implemented to improve anti-epidemic service in Russia: development and introduction of mobile application for anonymous social contacts tracking, introduction of mobile testing facilities, embedding household assistance for people that are required to isolate themselves, using hotels as hospitals for treating people with no or mild symptoms, planning investment in inpatient care facilities with respect to their possible reprofiling. Development of telemedicine technologies based on a model “physician—patient” is a useful measure for health policy. It is also possible to stimulate population’s demand by introducing governmental drug reimbursement program and earmarked grants on healthy food to people in need. Support for medical organizations is possible with calculating prices for medical services with respect to modern clinical guidelines. Finally, in order to protect patients’ rights, authority and responsibility of health insurance companies could be increased in a number of regional pilot projects. Introduction of these measures would help achieve national goals that were set by the presidential decree No. 204 from May 07, 2018.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.